TrappBDPetersonJRansohoffRM. Axonal transection in the lesions of multiple sclerosis. N Engl J Med1998; 338: 278–285.
2.
ConfavreuxCVukusicSMoreauT. Relapses and progression of disability in multiple sclerosis. N Engl J Med2000; 343: 1430–1438.
3.
ConfavreuxCVukusicSAdeleineP. Early clinical predictors and progression of irreversible disability in multiple sclerosis: An amnesic process. Brain2003; 126 (Pt 4): 770–782.
4.
ColesAJWingMGMolyneuxP. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol1999; 46: 296–304.
5.
ColesAJCompstonDASelmajKW. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med2008; 359: 1786–1801.
6.
HawkerKO’ConnorPFreedmanPS. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol2009; 66: 460–471.
7.
BieberAJKerrSRodriguezM. Efficient central nervous system remyelination requires T cells. Ann Neurol2003; 53: 680–684.
8.
KapoorRFurbyJHaytonT. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: A randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol2010; 9: 681–688.
9.
StadelmannC. Multiple sclerosis as a neurodegenerative disease: Pathology, mechanisms and therapeutic implications. Curr Opin Neurol2011; 24: 224–229.
